Sector: Health Care
Director information for EDGEWISE THERAPEUTICS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ALAN RUSSELL, Ph.D. | DIRECTOR, CO-FOUNDER AND CHIEF SCIENTIFIC OFFICER; Co-Founder, Chief Scientific Officer and Director | 56 | ["Edgewise Therapeutics, Inc., Chief Scientific Officer","Co-founder of the Company","Chief Scientific Officer since June 2017","Former Vice President and Head of the Muscle Metabolism Discovery Performance Unit at GlaxoSmithKline","Former Associate Director of Muscle Biology and Therapeutics at Cytokinetics","Adjunct Professor at the University of Colorado Boulder since November 2017","B.Pharm. in pharmacy and pharmacology and a Ph.D. in cell biology and gene therapy from the University of Bath","Postdoctoral Fellow at the Stanford University School of Medicine"] | [] | 2026 |
| ARLENE M. MORRIS | Director; DIRECTOR | 74 | ["Willow Advisors, LLC, Chief Executive Officer","Chief Executive Officer of Willow Advisors, LLC","Chief Executive Officer of Syndax Pharmaceuticals, Inc.","President and Chief Executive Officer of Affymax, Inc.","Management and executive positions at Clearview Projects, Inc.","Management and executive positions at Coulter Pharmaceutical, Inc.","Management and executive positions at Scios Inc.","Management and executive positions at Johnson & Johnson"] | ["Nominating & Corporate Governance","Compensation","Audit"] | 2026 |
| BADREDDIN EDRIS, Ph.D. | Director and Co-Founder; DIRECTOR AND CO-FOUNDER | 39 | ["Beeline Medicines Corporation, President and Chief Operating Officer","Co-founder of the Company","President and Chief Operating Officer of Beeline Medicines Corporation","Venture Partner at The Column Group, LLC","Chief Operating Officer of SpringWorks Therapeutics, Inc.","Chief Business Officer of SpringWorks","Investment and operating professional on the private equity team at OrbiMed Advisors LLC","Co-founded and held an operating role at Silverback Therapeutics, Inc.","Management consultant in the healthcare practice at Bain & Co Inc.","B.I.S. in microbiology from Weber State University","M.S. in biology from Stanford University","Ph.D. in genetics from Stanford University School of Medicine"] | ["Compensation"] | 2026 |
| CHRISTOPHER MARTIN | Director | 50 | ["Verona Pharma plc, Chief Commercial Officer","Extensive experience in the biopharmaceutical industry","Commercial expertise"] | ["Nominating & Corporate Governance"] | 2026 |
| Joanne M. Donovan, M.D., Ph.D. | Chief Medical Officer | 69 | [] | [] | 2026 |
| JONATHAN FOX, M.D., Ph.D. | Director | 69 | ["BridgeBio Pharma, Inc., President and Chief Medical Officer","President and Chief Medical Officer at BridgeBio Pharma, Inc.","Chief Medical Officer of MyoKardia, Inc.","Senior advisor at MyoKardia, Inc.","Consultant at Nigel-Montgomery, LLC","Various senior positions at SmithKline Beecham, Merck Research Laboratories, AstraZeneca","Adjunct faculty at Stanford University Cardiovascular Institute","Board member at ML BioSolutions","Trustee of the Lankenau Institute for Medical Research","A.B. in biology from the University of Chicago","Ph.D. in experimental pathology from the University of Chicago","M.D. from the University of Chicago","Training in Internal Medicine and Cardiology at Duke University","ABIM Certified in Cardiovascular Diseases","Fellow of the American College of Cardiology"] | ["Nominating & Corporate Governance"] | 2026 |
| JONATHAN ROOT, M.D. | Director; DIRECTOR | 66 | ["U.S. Venture Partners, General Partner","US Venture Partners, General Partner","General Partner of U.S. Venture Partners","Managing Member of several U.S. Venture Partners’ funds","Board member of Carlsmed, Inc.","Board member of Omada Health, Inc.","Former board member of Inari Medical, Inc.","Former board member of OncoMed Pharmaceuticals, Inc.","Former board member of eFFECTOR Therapeutics, Inc.","Former board member of Silverback Therapeutics, Inc.","A.B. in economics from Dartmouth College","M.D. from the University of Florida College of Medicine","M.B.A. from Columbia Business School"] | ["Nominating & Corporate Governance","Compensation","Audit"] | 2026 |
| KEVIN KOCH, Ph.D. | President, Chief Executive Officer and Director | 65 | ["Edgewise Therapeutics, Inc., Chief Executive Officer","Venture Partner with OrbiMed Advisors LLC","Consultant in the biotech industry","Senior Vice President for Drug Discovery at Biogen Inc.","Co-founded Array BioPharma Inc.","Various positions with Pfizer Central Research"] | [] | 2026 |
| Laura Brege | DIRECTOR; Director; Chairperson | 68 | ["BridgeBio Pharma, Inc., Senior Advisor","Senior Advisor to BridgeBio Pharma, Inc.","Managing Director at Cervantes Life Science Partners, LLC","President and Chief Executive Officer at Nodality, Inc.","Executive Vice President and Chief Operating Officer at Onyx Pharmaceuticals, Inc.","General partner at Red Rock Capital Management","Senior Vice President and Chief Financial Officer at COR Therapeutics, Inc.","Vice President and Chief Financial Officer at Flextronics","Vice President and Treasurer of The Cooper Companies","Served on the boards of multiple biotechnology companies","audit committee financial expert","financial sophistication"] | ["Audit","Compensation"] | 2026 |
| LAURA BREGED | Director | 68 | ["BridgeBio Pharma, Inc., Senior Advisor"] | ["Audit","Compensation"] | 2026 |
| PETER THOMPSON, M.D. | Chairperson and Co-Founder | 66 | ["OrbiMed Advisors LLC, General Partner","Co-founded the Company","Chairperson of the board of directors","Partner at OrbiMed Advisors LLC","Chairman of Terremoto Biosciences, Inc.","Former President and Chief Executive Officer of Terremoto Biosciences, Inc.","Former Chief Executive Officer and President of Glia Biotherapeutics, Inc.","Former Chief Executive Officer and President of Terremoto Therapeutics Holdings, LLC","Board member of several public companies","Co-founded Silverback Therapeutics, Inc. and Cleave Biosciences Inc.","Previous executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation, and Becton, Dickinson and Company","Affiliate Professor of Neurosurgery at the University of Washington","Board-certified internist and oncologist","Holds numerous patents","Sc. B. in Molecular Biology and Mathematics from Brown University","M.D. from Brown University Medical School"] | [] | 2026 |
| Robert Blaustein, M.D., Ph.D. | Former Chief Development Officer | [] | [] | 2026 |
